Want to see HK:2877 full AI Analyst Report?
China Shineway Pharmaceutical Group Limited (2877) AI Stock Analysis
Top Page
China Shineway Pharmaceutical Group Limited
(HKEX:2877)
The score is driven primarily by strong financial quality (high margins and very low leverage) and attractive valuation (low P/E and high dividend yield). Technicals are supportive with the price above major moving averages, but the elevated RSI and recent revenue contraction temper the overall rating.
China Shineway Pharmaceutical Group Limited (2877) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 5.67B
- Dividend Yield
- 16.66%
- Average Volume (3M)
- 1.48M
- Price to Earnings (P/E)
- 6.1
- Beta (1Y)
- 0.50
- Revenue Growth
- -17.74%
- EPS Growth
- 1.12%
- Country
- Hong Kong
- Employees
- 2,656
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
China Shineway Pharmaceutical Group Limited Business Overview & Revenue Model
Company Description
As an investment holding enterprise, China Shineway Pharmaceutical Group Limited is dedicated to the development, production, and sale of traditional Chinese medicines throughout the People's Republic of China and Hong Kong. Its extensive product ran...
How the Company Makes Money
China Shineway Pharmaceutical Group Limited makes money mainly by manufacturing and selling pharmaceutical products, with its revenue primarily generated from the sale of its proprietary modernized TCM products. The company’s key revenue streams are...
China Shineway Pharmaceutical Group Limited Financial Statement Overview
Summary
Strong profitability (gross margin ~72%–75%, EBIT margin low-to-mid 20s, net margin ~30% in 2025) and an exceptionally conservative balance sheet (debt-to-equity ~0.04–0.05) support a high score. The key offset is weakening growth momentum with revenue declining in 2025 (~-8.7%) and some margin softening versus the 2023 peak; cash flow is positive and improving but shows volatility and limited 2025 coverage metric visibility.
Income Statement
76PositiveBalance Sheet
90Very PositiveCash Flow
70Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.65B | 3.14B | 3.78B | 4.52B | 3.95B | 3.22B |
| Gross Profit | 1.89B | 2.27B | 2.83B | 3.39B | 2.94B | 2.41B |
| EBITDA | 792.57M | 752.95M | 904.73M | 1.42B | 1.10B | 903.74M |
| Net Income | 797.97M | 949.95M | 840.05M | 969.51M | 722.77M | 556.67M |
Balance Sheet | ||||||
| Total Assets | 10.45B | 10.78B | 10.04B | 9.57B | 8.23B | 7.20B |
| Cash, Cash Equivalents and Short-Term Investments | 7.54B | 7.57B | 6.49B | 5.91B | 5.05B | 4.21B |
| Total Debt | 312.23M | 335.05M | 346.53M | 301.33M | 7.44M | 14.91M |
| Total Liabilities | 2.25B | 2.72B | 2.57B | 2.54B | 1.85B | 1.30B |
| Stockholders Equity | 8.20B | 8.07B | 7.47B | 7.03B | 6.38B | 5.90B |
Cash Flow | ||||||
| Free Cash Flow | 891.41M | 974.13M | 823.02M | 788.31M | 980.21M | 609.52M |
| Operating Cash Flow | 1.07B | 1.17B | 963.13M | 932.63M | 1.11B | 703.15M |
| Investing Cash Flow | 73.99M | 222.03M | -272.11M | -49.54M | -45.42M | 395.01M |
| Financing Cash Flow | -443.05M | -375.01M | -392.48M | -26.74M | -250.04M | -828.93M |
China Shineway Pharmaceutical Group Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2877, the sentiment is Positive. The current price of 7.50 is above the 20-day moving average (MA) of 7.38, above the 50-day MA of 7.06, and above the 200-day MA of 6.84, indicating a bullish trend. The MACD of 0.07 indicates Positive momentum. The RSI at 59.04 is Neutral, neither overbought nor oversold. The STOCH value of 39.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2877.
China Shineway Pharmaceutical Group Limited Peers Comparison
Overall Rating
- HK:287781Outperform
HK:263370Outperform
HK:051259Neutral
HK:071954Neutral
HK:393354Neutral
HK:057052.75Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2877 | 81Outperform | HKD 5.67B | 6.07 | 9.81% | 16.66% | -17.74% | 1.12% |
| HK:2633 | 70Outperform | HKD 1.78B | 6.19 | 13.26% | 9.67% | -0.47% | -0.40% |
| HK:0512 | 59Neutral | HKD 15.30B | 13.45 | 6.61% | 3.92% | 7.35% | -45.49% |
| HK:0719 | 54Neutral | HKD 8.28B | 37.23 | 4.32% | 3.22% | -0.52% | -37.60% |
| HK:3933 | 54Neutral | HKD 13.46B | 20.80 | 3.12% | 4.38% | -12.86% | -83.10% |
| HK:0570 | 53Neutral | HKD 5.89B | -4.81 | -4.98% | 0.30% | -15.80% | -298.94% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2877 | China Shineway Pharmaceutical Group Limited | 7.50 | 1.13 | 17.67% | |
| HK:3933 | The United Laboratories International | 6.83 | -5.69 | -45.46% | |
| HK:0570 | China Traditional Chinese Medicine Holdings Co | 1.17 | -1.16 | -49.79% | |
| HK:2633 | Jacobson Pharma Corporation Limited | 0.94 | -0.42 | -30.74% | |
| HK:0512 | Grand Pharmaceutical Group Limited | 4.31 | -4.18 | -49.26% | |
| HK:0719 | Shandong Xinhua Pharmaceutical Company Limited Class H | 5.35 | -1.42 | -20.94% |
China Shineway Pharmaceutical Group Limited Corporate Events
China Shineway Board to Weigh Special Interim Dividend
China Shineway Pharmaceutical Group Limited has scheduled a board meeting for 18 September 2026 to consider declaring a special interim dividend for its shareholders. The move signals the company’s intention to return additional capital to inve...
China Shineway Pharma Announces Second Interim Dividend for Fiscal 2026
China Shineway Pharmaceutical Group Limited, a Hong Kong-listed pharmaceutical company under stock code 02877, operates in the healthcare sector by issuing equity to investors in renminbi with corresponding Hong Kong dollar settlements. Its board is...
Shineway Profit Falls Amid TCM Headwinds but Dividend Payout Stays Strong
China Shineway reported a sharp deterioration in its interim performance for the six months ended 30 June 2026 as the TCM industry came under pressure from medical insurance cost controls, centralized procurement, weak terminal demand and destocking...
China Shineway to Review Interim Results and Consider Dividend at August Board Meeting
China Shineway Pharmaceutical Group Limited has scheduled a board meeting for 27 August 2026 to review and approve its interim results for the six months ended 30 June 2026. The board will also consider the declaration of a dividend at the meeting, a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 10, 2026